SCHEMBL117529

SCHEMBL117529

CCOP(=O)(OCC)OCCOCCOP(=O)(OCC)OCC

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.68
CYP3A4 P08684 2/20 0.67
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PPARD Q03181 2/20 0.36
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25176944 0.93 TSHR (0.59) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL30909310 0.93 TSHR (0.59) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL30909315 0.93 TSHR (0.59) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL25167784 0.93 TSHR (0.59) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL8962338 0.92 TSHR (0.81) TSHRCYP3A4ALDH1A1TP53TDP1
Ammonia Solution, Strong SCHEMBL28386014 0.90 TSHR (0.62) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL1885863 0.90 TSHR (0.67) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL872327 0.90 TSHR (0.67) TSHRCYP3A4ALDH1A1TP53TDP1
SCHEMBL8916348 0.89 TSHR (0.88) TSHRCYP3A4
SCHEMBL10416347 0.89 TSHR (0.55) TSHRCYP3A4ALDH1A1TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof JAL THERAPEUTICS LLC (US) 2026-01-15 US claimed
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 WO claimed
US-8475934-B2 Flame-retardant timber materials LANXESS DEUTSCHLAND GMBH (DE) 2013-07-02 US claimed
US-20120058358-A1 Flame-retardant timber materials LANXESS DEUTSCHLAND GMBH (DE) 2012-03-08 US claimed
EP-1746129-B1 Halogenfree, flameretardant polyurethane foams LANXESS DEUTSCHLAND GMBH (DE) 2009-01-14 EP claimed
US-20070021516-A1 Halogen-free, flame-retardant polyurethane foams LANXESS DEUTSCHLAND GMBH 2007-01-25 US claimed
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof JAL THERAPEUTICS LLC (US) 2026-01-15 US disclosed
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 WO disclosed
EP-3064540-B1 FLAME RETARDANT CELLULOSE-ESTER PREPARATIONS LANXESS DEUTSCHLAND GMBH (DE) 2018-05-23 EP disclosed
US-9920081-B2 Halogen-free poly(alkylene phosphates) LANXESS DEUTSCHLAND GMBH (DE) 2018-03-20 US disclosed
US-20160257704-A1 FLAME-RETARDANT CELLULOSE ESTER PREPARATIONS LANXESS DEUTSCHLAND GMBH (DE) 2016-09-08 US disclosed
EP-3064540-A1 FLAME RETARDANT CELLULOSE-ESTER PREPARATIONS LANXESS Deutschland GmbH (DE) 2016-09-07 EP disclosed
US-20140024734-A1 HALOGEN-FREE POLY(ALKYLENE PHOSPHATES) LANXESS DEUTSCHLAND GMBH (DE) 2014-01-23 US disclosed
EP-2425945-A2 Flame resistant wooden materials LANXESS Deutschland GmbH (DE) 2012-03-07 EP disclosed
EP-2425944-A1 Flame resistant wooden materials LANXESS Deutschland GmbH (DE) 2012-03-07 EP disclosed
EP-1746129-B1 Halogenfree, flameretardant polyurethane foams LANXESS DEUTSCHLAND GMBH (DE) 2009-01-14 EP disclosed
US-20070021516-A1 Halogen-free, flame-retardant polyurethane foams LANXESS DEUTSCHLAND GMBH 2007-01-25 US disclosed
US-20070021516-A1 Halogen-free, flame-retardant polyurethane foams LANXESS DEUTSCHLAND GMBH 2007-01-25 US disclosed
US-20070021516-A1 Halogen-free, flame-retardant polyurethane foams LANXESS DEUTSCHLAND GMBH 2007-01-25 US disclosed
EP-1746129-A1 Halogenfree, flameretardant polyurethane foams Lanxess Deutschland GmbH (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257704-A1 FLAME-RETARDANT CELLULOSE ESTER PREPARATIONS FIBP, PFKFB2, FABP4 TSHR 1304/4885CYP3A4 2152/4885ALDH1A1 2028/4885
US-20120058358-A1 Flame-retardant timber materials PFAS, CYP4F3, TARS2 TSHR 226/4885CYP3A4 100/4885ALDH1A1 3321/4885
US-20260015372-A1 Organophosphorous Compounds and Uses Thereof ACHE, BCHE, MUSK TSHR 708/4885CYP3A4 1005/4885ALDH1A1 4365/4885
US-20140024734-A1 HALOGEN-FREE POLY(ALKYLENE PHOSPHATES) PUF60, PCBP1, FFAR3 TSHR 1431/4885CYP3A4 2735/4885ALDH1A1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.